Abstract:The amount of dose reduction on changing from low dose rate (LDR) brachytherapy to medium dose rate (MDR) or high dose rate (HDR) afterloading has been the subject of much debate. The magnitude of reduction depends, together with other possible factors, on two radiobiological parameters: the alpha/beta ratio and the half-time of repair of the relevant tissues. In an attempt to extract these radiobiological parameters for the late rectal complications observed in our previously published clinical results four different schedules using MDR and one using LDR are analyzed. The percentage incidence of complications was a function of increasing biologically effective dose (BED), but would yield nonsense scattergrams if plotted against raw total dose. In addition, for three other published MDR series, three LDR series, and two HDR series, the incidence of rectal complications is plotted against BED to examine the predictive potential of using BED as the surrogate of total dose. Our own results were published in 1996, consisting of 102 patients treated at the LDR of 0.44 Gy/hr and 88 patients treated by four different schedules using an MDR of 1.6-1.7 Gy/hr. Follow-up is at least 3 years in all schedules. The linear quadratic formula including the "g" dose rate factor was used to analyze them, assuming exponential repair of the repairable beta term. First, multivariate and profile likelihood analyses were carried out to obtain estimates of alpha/beta and T1/2 for rectal late responding tissues. Then graphs of incidence of rectal complications vs. BED were constructed, assuming alpha/beta = 3 Gy and T1/2 = 1.5 hr, values which had not been contradicted by the multivariate analysis. Graphs were drawn both for "all grades including mild reactions" (grades 1 + 2 + 3) and for "serious" complications (grade 3 in our system). In addition, other published cervical brachytherapy series were reviewed, with calculation of their BEDs if not published by the authors. It was necessary to review and compare their grading systems, so that "mild and moderate" (grades 1 and 2) could be contrasted with "serious" (grades 3 and 4 or 5 in various systems). Comparisons were made with other published results, including three LDR, three MDR, and two HDR series spanning from 1982 to 1997. The BEDs at which the incidence of rectal complications rose above the arbitrary level of 10% were compared for all three ranges of dose rate. The multivariate analysis gave estimates of alpha/beta and T1/2 which were not significantly different from 3 Gy and 1.5 hr, respectively, so these values were used to compute the BEDs for the subsequent comparisons. It was found that the graphs of incidence of rectal complications for "all grades including mild" agreed rather better between all series than might have been expected, within a provisional (10%) threshold BED of range 100-123 Gy3 (60-74 Gy given as 2 Gy fractionated external beam or as LDR). The dose-response curves diverged above these values, as expected until common grading systems such as SOMA/ LENT become more widely used. For "serious" complications the 10% incidence occurred at a median BED of 140 Gy3 (84 Gy given as 2 Gy fractionated external beam or as LDR), range 124-155 Gy3. The use of BED (or extrapolated response dose), assuming alpha/beta = 3 Gy and T1/2 = 1.5 hr, instead of total dose, enabled incidence of late rectal complications in cervical brachytherapy with LDR, MDR, and HDR to be plotted in a reasonably consistent way. This does not mean that those parameter values have been definitively determined, but they appear to be provisional values that may be of use in comparing the expected effects of new schedules until better values are obtained from greater use of common grading systems.

Key comparison BIPM.RI(I)-K8 of high dose-rate 192 Ir brachytherapy standards for reference air kerma rate of the LNE-LNHB and the BIPM

Key comparison BIPM.RI(I)-K8 of high dose-rate 192 Ir brachytherapy standards for reference air kerma rate of the PTB and the BIPM

Key comparison BIPM.RI(I)-K5 of the air-kerma standards of the CIEMAT, Spain and the BIPM in 137 Cs gamma radiation

Key comparison BIPM.RI(I)-K5 of the air-kerma standards of the BEV, Austria and the BIPM in 137 Cs gamma radiation

Key comparison BIPM.RI(I)-K2 of the air-kerma standards of the PTB, Germany, and the BIPM in low-energy x-rays

Key comparison BIPM.RI(I)-K3 of the air-kerma standards of the PTB, Germany, and the BIPM in medium-energy x-rays

Key comparison BIPM.RI(I)-K7 of the air-kerma standards of the BFKH, Hungary, and the BIPM in mammography x-rays

Comparison of the standards for absorbed dose to water of the IAEA and the KRISS, Korea in accelerator photon beams

International comparison of measurements of neutron source emission rate (2016-2021) - CCRI(III)-K9.Cf.2016

Update of the BIPM comparison BIPM.RI(II)-K1.Tb-161 of activity measurements of the radionuclide 161 Tb to include the 2022 result of the NPL (United Kingdom)

Update of the BIPM comparison BIPM.RI(II)-K1.Cs-137 of activity measurements of the radionuclide 137 Cs to include the 2014 result of the NRC (Canada) and the 2018 result of the TENMAK-NÜKEN (Türkiye)

Update of the BIPM comparison BIPM.RI(II)-K1.Co-57 of activity measurements of the radionuclide 57 Co to include the 2023 result of the BEV (Austria)

Update of the BIPM comparison BIPM.RI(II)-K1.Ge-68 of activity measurements of the radionuclide 68 Ge to include the 2021 result of the NIM (China)

Update of the BIPM comparison BIPM.RI(II)-K1.Cr-51 of activity measurements of the radionuclide 51 Cr to include the 2012 result of the KRISS (Rep. of Korea), the 2022 result of the POLATOM (Poland), and to link the 2022 EURAMET.RI(II)-K2.Cr-51 comparison

New calculations of neutron kerma coefficients and dose equivalent.

Update of the BIPM comparison BIPM.RI(II)-K1.Zn-65 of activity measurements of the radionuclide 65 Zn to include the 2015 result of the LNMRI-IRD (Brazil) and the 2018 result of the LNE-LNHB (France)

Effective Dose for Patients Undergoing Coronary and Femoral Intravascular Radiotherapy Involving an HDR 192ir Source.

Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix

Bilateral Comparison of 1.018 V and 10 V Standards Between the KRISS (republic of Korea) and the BIPM, February 2008 (part of the Ongoing BIPM Key Comparison BIPM.EM-K11.a and B)

Bilateral comparison of 1.018 V and 10 V standards between INRIM (Italy) and the BIPM, November to December 2023 (part of the ongoing BIPM key comparison BIPM.EM-K11.a and b)

New National Air-Kerma Standard for Low-Energy Electronic Brachytherapy Sources